The Parker Institute for Cancer Immunotherapy Partners with Xyphos Biosciences to Develop Universal Programmable CAR-T Cells for Cancer Treatment
James Allison, Parker Institute for Cancer Immunotherapy Director, Wins 2018 Nobel Prize in Medicine or Physiology for Research on Immune Checkpoint Inhibitors
The Parker Institute for Cancer Immunotherapy enables real collaboration, accelerating ambitious research to deliver new immunotherapies engineered to save lives.
World-renowned experts from leading cancer centers are at the forefront of our research.
Open in Twitter Parker Institute @parkerici New article @ScienceMagazine by PICI CEO and President Jeff Bluestone (@kickassscience1): Regulatory T cells and wh… https://t.co/bxJMiicOgW 22 hours ago
Open in Twitter Parker Institute @parkerici New data on the IO industry published by @CancerResearch in @NatRevDrugDisc evaluates trends in the global landscap… https://t.co/amNF79cOYd 22 hours ago